The thesis
SilentDip is built on a tidy behavioural premise: a stock that falls hard without a salient negative headline is usually reacting to noise, and noise tends to revert. The same drop carrying genuine bad news keeps drifting lower. So the strategy only buys when two conditions line up — oversold technicals and an absence of negative sentiment — then exits as the name mean-reverts toward its SMA20 or as RSI normalizes.
The idea isn't plucked from thin air. It leans on Clinch, He, Landsman & Li (SSRN working paper, Nov 2025), which itself extends Chan's 2003 work on how prices react to news versus no-news. Grounding a signal in published research doesn't make it profitable, but it's a healthier starting point than a pattern reverse-engineered from a price chart.
Recent activity
It has been a quiet fortnight. SilentDip's last fill was a 29-share buy of BAC at $51 on 14 October. Every scheduled run since — six of them, from 21 to 28 October — reports 0 executed, 0 rejected. The account holds $8,515.71 in cash against a total of roughly $9,992, meaning it is sitting on essentially one position and a lot of dry powder.
That idleness is by design: if no name in the 24-stock large-cap universe is both oversold and headline-clean, the strategy does nothing. The flip side is that the live total has hovered just under its $10k starting line all month — effectively flat to marginally negative since going live.
Validation and backtest
The out-of-sample record is where SilentDip earns attention. Across four walk-forward folds spanning 2021–2026, all four were positive. Later folds are the strongest: fold 3 returned 26.26% (Sharpe 1.84) and the most recent fold 4 returned 16.75% at Sharpe 1.91 with a tiny 2.39% drawdown.
The full backtest shows a 52.62% total return over 1,279 days — a more sober 8.69% CAGR — with a 70.55% win rate across 294 trades and a 10.38% max drawdown. A probabilistic Sharpe ratio of 0.991 is excellent, and crucially the deflated Sharpe of 0.563, which haircuts for the 42 trials run during the search, stays above 0.5. In plain terms: even after penalising for how many variants were tested, the edge is more likely real than not.
Strengths and risks
Strengths: every fold positive, a high and stable win rate, a research-backed thesis, and a deflated Sharpe that survives multiple-testing scrutiny.
Risks: the headline 52.62% flatters a modest 8.69% compounded return. The overall Sharpe of 1.03 is only decent, turnover is extreme at 4,192%, and the DSR of 0.563 is far from the 0.991 PSR — the edge is genuine but thin. Most immediately, the live account has produced no return and almost no trades since inception. A strategy that waits is disciplined; a strategy that only waits earns nothing. The coming weeks of live fills, not the backtest, will tell us which this is.